{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:58:10Z","timestamp":1790481490225,"version":"4.1.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40291-025-00810-9","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:25:33Z","timestamp":1755847533000},"page":"741-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Amino Acid Transporters in Glioblastoma: Implications for Diagnosis, Disease Monitoring, Therapeutic Targeting, and Drug Delivery"],"prefix":"10.1007","volume":"29","author":[{"given":"Emanuella M.","family":"Brito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M","family":"Ahye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A","family":"Lieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajini","family":"Hettiarachchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. Moreno","family":"Hollweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrin B","family":"Safar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-2971","authenticated-orcid":false,"given":"Regina M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"810_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22034\/APJCP.2017.18.1.3","volume":"18","author":"F Hanif","year":"2017","unstructured":"Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18:3\u20139. https:\/\/doi.org\/10.22034\/APJCP.2017.18.1.3.","journal-title":"Asian Pac J Cancer Prev"},{"key":"810_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171: 105780. https:\/\/doi.org\/10.1016\/j.phrs.2021.105780.","journal-title":"Pharmacol Res"},{"key":"810_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fonc.2018.00419","volume":"8","author":"KK Jain","year":"2018","unstructured":"Jain KK. A critical overview of targeted therapies for glioblastoma. Front Oncol. 2018;8:419. https:\/\/doi.org\/10.3389\/fonc.2018.00419.","journal-title":"Front Oncol"},{"key":"810_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(24)00476-9","volume":"24","author":"JH Pedder","year":"2025","unstructured":"Pedder JH, Sonabend AM, Cearns MD, et al. Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease. Lancet Neurol. 2025;24:246\u201360. https:\/\/doi.org\/10.1016\/S1474-4422(24)00476-9.","journal-title":"Lancet Neurol"},{"key":"810_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8:217. https:\/\/doi.org\/10.1038\/s41392-023-01481-w.","journal-title":"Signal Transduct Target Ther"},{"key":"810_CR6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3181\/00379727-149-38889","volume":"149","author":"WH Oldendorf","year":"1975","unstructured":"Oldendorf WH, Brown WJ. Greater number of capillary endothelial cell mitochondria in brain than in muscle. Proc Soc Exp Biol Med. 1975;149:736\u20138. https:\/\/doi.org\/10.3181\/00379727-149-38889.","journal-title":"Proc Soc Exp Biol Med"},{"key":"810_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0026-2862(85)90042-1","volume":"30","author":"BL Coomber","year":"1985","unstructured":"Coomber BL, Stewart PA. Morphometric analysis of CNS microvascular endothelium. Microvasc Res. 1985;30:99\u2013115. https:\/\/doi.org\/10.1016\/0026-2862(85)90042-1.","journal-title":"Microvasc Res"},{"key":"810_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3389\/fphys.2020.00973","volume":"11","author":"R Zaragoza","year":"2020","unstructured":"Zaragoza R. Transport of amino acids across the blood-brain barrier. Front Physiol. 2020;11:973. https:\/\/doi.org\/10.3389\/fphys.2020.00973.","journal-title":"Front Physiol"},{"key":"810_CR9","doi-asserted-by":"publisher","first-page":"E1167","DOI":"10.1152\/ajpendo.00193.2003","volume":"285","author":"RL O'Kane","year":"2003","unstructured":"O\u2019Kane RL, Hawkins RA. Na+-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood\u2013brain barrier. Am J Physiol Endocrinol Metab. 2003;285:E1167-1173. https:\/\/doi.org\/10.1152\/ajpendo.00193.2003.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"810_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1211\/0022357011775794","volume":"53","author":"Y Kido","year":"2001","unstructured":"Kido Y, Tamai I, Uchino H, Suzuki F, Sai Y, Tsuji A. Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier. J Pharm Pharmacol. 2001;53:497\u2013503. https:\/\/doi.org\/10.1211\/0022357011775794.","journal-title":"J Pharm Pharmacol"},{"key":"810_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.15171\/bi.2016.30","volume":"6","author":"J Barar","year":"2016","unstructured":"Barar J, Rafi MA, Pourseif MM, Omidi Y. Blood\u2013brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6:225\u201348. https:\/\/doi.org\/10.15171\/bi.2016.30.","journal-title":"Bioimpacts"},{"key":"810_CR12","first-page":"432","volume":"42","author":"PL Jager","year":"2001","unstructured":"Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432\u201345.","journal-title":"J Nucl Med"},{"key":"810_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519\u201330. https:\/\/doi.org\/10.1085\/jgp.8.6.519.","journal-title":"J Gen Physiol"},{"key":"810_CR14","doi-asserted-by":"publisher","first-page":"13194","DOI":"10.1074\/jbc.M115.700534","volume":"291","author":"A Broer","year":"2016","unstructured":"Broer A, Rahimi F, Broer S. Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells. J Biol Chem. 2016;291:13194\u2013205. https:\/\/doi.org\/10.1074\/jbc.M115.700534.","journal-title":"J Biol Chem"},{"key":"810_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2010.08.009","volume":"18","author":"JB Wang","year":"2010","unstructured":"Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18:207\u201319. https:\/\/doi.org\/10.1016\/j.ccr.2010.08.009.","journal-title":"Cancer Cell"},{"key":"810_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40478-020-01114-1","volume":"9","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Sasayama T, Nagashima H, et al. Glioma cells require one-carbon metabolism to survive glutamine starvation. Acta Neuropathol Commun. 2021;9:16. https:\/\/doi.org\/10.1186\/s40478-020-01114-1.","journal-title":"Acta Neuropathol Commun"},{"key":"810_CR17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/s41416-020-0794-x","volume":"122","author":"AL Engel","year":"2020","unstructured":"Engel AL, Lorenz NI, Klann K, et al. Serine-dependent redox homeostasis regulates glioblastoma cell survival. Br J Cancer. 2020;122:1391\u20138. https:\/\/doi.org\/10.1038\/s41416-020-0794-x.","journal-title":"Br J Cancer"},{"key":"810_CR18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1172\/JCI78239","volume":"125","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Sasayama T, Irino Y, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Investig. 2015;125:1591\u2013602. https:\/\/doi.org\/10.1172\/JCI78239.","journal-title":"J Clin Investig"},{"key":"810_CR19","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.7150\/thno.53506","volume":"11","author":"JL Caniglia","year":"2021","unstructured":"Caniglia JL, Jalasutram A, Asuthkar S, et al. Beyond glucose: alternative sources of energy in glioblastoma. Theranostics. 2021;11:2048\u201357. https:\/\/doi.org\/10.7150\/thno.53506.","journal-title":"Theranostics."},{"key":"810_CR20","first-page":"5004","volume":"12","author":"F Qian","year":"2022","unstructured":"Qian F, Xu H, Zhang Y, Li L, Yu R. Methionine deprivation inhibits glioma growth through downregulation of CTSL. Am J Cancer Res. 2022;12:5004\u201318.","journal-title":"Am J Cancer Res"},{"key":"810_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105363","volume":"158","author":"M Obara-Michlewska","year":"2022","unstructured":"Obara-Michlewska M. The tryptophan metabolism, kynurenine pathway and oxidative stress\u2014implications for glioma pathobiology. Neurochem Int. 2022;158: 105363. https:\/\/doi.org\/10.1016\/j.neuint.2022.105363.","journal-title":"Neurochem Int"},{"key":"810_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730289","volume":"12","author":"Y Xu","year":"2021","unstructured":"Xu Y, Zhang H, Sun Q, et al. Immunomodulatory effects of tryptophan metabolism in the glioma tumor microenvironment. Front Immunol. 2021;12: 730289. https:\/\/doi.org\/10.3389\/fimmu.2021.730289.","journal-title":"Front Immunol"},{"key":"810_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938847","volume":"12","author":"X Hou","year":"2022","unstructured":"Hou X, Chen S, Zhang P, Guo D, Wang B. Targeted arginine metabolism therapy: a dilemma in glioma treatment. Front Oncol. 2022;12: 938847. https:\/\/doi.org\/10.3389\/fonc.2022.938847.","journal-title":"Front Oncol"},{"key":"810_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s11060-019-03351-4","volume":"146","author":"S Ohba","year":"2020","unstructured":"Ohba S, Hirose Y. l-Asparaginase and 6-diazo-5-oxo-l-norleucine synergistically inhibit the growth of glioblastoma cells. J Neurooncol. 2020;146:469\u201375. https:\/\/doi.org\/10.1007\/s11060-019-03351-4.","journal-title":"J Neurooncol"},{"key":"810_CR25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.tibs.2018.05.003","volume":"43","author":"P Kandasamy","year":"2018","unstructured":"Kandasamy P, Gyimesi G, Kanai Y, Hediger MA. Amino acid transporters revisited: new views in health and disease. Trends Biochem Sci. 2018;43:752\u201389. https:\/\/doi.org\/10.1016\/j.tibs.2018.05.003.","journal-title":"Trends Biochem Sci"},{"key":"810_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41598-018-37390-0","volume":"9","author":"EH Suh","year":"2019","unstructured":"Suh EH, Hackett EP, Wynn RM, et al. In vivo assessment of increased oxidation of branched-chain amino acids in glioblastoma. Sci Rep. 2019;9:340. https:\/\/doi.org\/10.1038\/s41598-018-37390-0.","journal-title":"Sci Rep"},{"key":"810_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2967\/jnumed.122.264859","volume":"64","author":"N Galldiks","year":"2023","unstructured":"Galldiks N, Lohmann P, Fink GR, Langen KJ. Amino acid PET in neurooncology. J Nucl Med. 2023;64:693\u2013700. https:\/\/doi.org\/10.2967\/jnumed.122.264859.","journal-title":"J Nucl Med"},{"key":"810_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010090","author":"R De Marco","year":"2022","unstructured":"De Marco R, Pesaresi A, Bianconi A, et al. A systematic review of amino acid PET imaging in adult-type high-grade glioma surgery: a neurosurgeon\u2019s perspective. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers15010090.","journal-title":"Cancers (Basel)"},{"key":"810_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020197","author":"S Jakobsen","year":"2024","unstructured":"Jakobsen S, Nielsen CU. Exploring amino acid transporters as therapeutic targets for cancer: an examination of inhibitor structures, selectivity issues, and discovery approaches. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16020197.","journal-title":"Pharmaceutics"},{"key":"810_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cell.2015.07.022","volume":"162","author":"A Cesar-Razquin","year":"2015","unstructured":"Cesar-Razquin A, Snijder B, Frappier-Brinton T, et al. A call for systematic research on solute carriers. Cell. 2015;162:478\u201387. https:\/\/doi.org\/10.1016\/j.cell.2015.07.022.","journal-title":"Cell"},{"key":"810_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2025.01.015","volume":"188","author":"A Khan","year":"2025","unstructured":"Khan A, Liu Y, Gad M, Kenny TC, Birsoy K. Solute carriers: the gatekeepers of metabolism. Cell. 2025;188:869\u201384. https:\/\/doi.org\/10.1016\/j.cell.2025.01.015.","journal-title":"Cell"},{"key":"810_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s44320-025-00108-2","volume":"21","author":"U Goldmann","year":"2025","unstructured":"Goldmann U, Wiedmer T, Garofoli A, et al. Data- and knowledge-derived functional landscape of human solute carriers. Mol Syst Biol. 2025;21:599\u2013631. https:\/\/doi.org\/10.1038\/s44320-025-00108-2.","journal-title":"Mol Syst Biol"},{"key":"810_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/neuonc\/now247","volume":"19","author":"RL Bowman","year":"2017","unstructured":"Bowman RL, Wang Q, Carro A, Verhaak RG, Squatrito M. Gliovis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 2017;19:139\u201341. https:\/\/doi.org\/10.1093\/neuonc\/now247.","journal-title":"Neuro Oncol"},{"key":"810_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.603837","volume":"8","author":"Z Wei","year":"2020","unstructured":"Wei Z, Liu X, Cheng C, Yu W, Yi P. Metabolism of amino acids in cancer. Front Cell Dev Biol. 2020;8: 603837. https:\/\/doi.org\/10.3389\/fcell.2020.603837.","journal-title":"Front Cell Dev Biol."},{"key":"810_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41419-024-06435-w","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen J, Cui L, Lu S, Xu S. Amino acid metabolism in tumor biology and therapy. Cell Death Dis. 2024;15:42. https:\/\/doi.org\/10.1038\/s41419-024-06435-w.","journal-title":"Cell Death Dis"},{"key":"810_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.mam.2013.01.001","volume":"34","author":"Y Kanai","year":"2013","unstructured":"Kanai Y, Clemencon B, Simonin A, et al. The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013;34:108\u201320. https:\/\/doi.org\/10.1016\/j.mam.2013.01.001.","journal-title":"Mol Aspects Med"},{"key":"810_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","volume":"52","author":"EL Lieu","year":"2020","unstructured":"Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. Exp Mol Med. 2020;52:15\u201330. https:\/\/doi.org\/10.1038\/s12276-020-0375-3.","journal-title":"Exp Mol Med"},{"key":"810_CR38","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.2147\/IJGM.S350986","volume":"15","author":"X Zhong","year":"2022","unstructured":"Zhong X, Yao L, Xu L, et al. Comprehensive analysis of potential correlation between solute carrier 1A (SLC1A) family and lung adenocarcinoma. Int J Gen Med. 2022;15:2101\u201317. https:\/\/doi.org\/10.2147\/IJGM.S350986.","journal-title":"Int J Gen Med"},{"key":"810_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.mam.2012.10.007","volume":"34","author":"D Fotiadis","year":"2013","unstructured":"Fotiadis D, Kanai Y, Palacin M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34:139\u201358. https:\/\/doi.org\/10.1016\/j.mam.2012.10.007.","journal-title":"Mol Aspects Med"},{"key":"810_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119393","author":"F Anagnostakis","year":"2023","unstructured":"Anagnostakis F, Kokkorakis M, Markouli M, Piperi C. Impact of solute carrier transporters in glioma pathology: a comprehensive review. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24119393.","journal-title":"Int J Mol Sci"},{"key":"810_CR41","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1089\/scd.2017.0123","volume":"26","author":"MD Polewski","year":"2017","unstructured":"Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Aboody KS. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties. Stem Cells Dev. 2017;26:1236\u201346. https:\/\/doi.org\/10.1089\/scd.2017.0123.","journal-title":"Stem Cells Dev"},{"key":"810_CR42","doi-asserted-by":"publisher","first-page":"602","DOI":"10.21037\/tcr-20-2744","volume":"10","author":"W Gong","year":"2021","unstructured":"Gong W, Chen Y, Zhang Y. Prognostic and clinical significance of solute carrier family 7 member 1 in ovarian cancer. Transl Cancer Res. 2021;10:602\u201312. https:\/\/doi.org\/10.21037\/tcr-20-2744.","journal-title":"Transl Cancer Res"},{"key":"810_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12957-018-1535-y","volume":"16","author":"L Shen","year":"2018","unstructured":"Shen L, Qian C, Cao H, Wang Z, Luo T, Liang C. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma. World J Surg Oncol. 2018;16:235. https:\/\/doi.org\/10.1186\/s12957-018-1535-y.","journal-title":"World J Surg Oncol"},{"key":"810_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119303","volume":"1869","author":"X Wang","year":"2022","unstructured":"Wang X, Chen J, Liu XH, et al. Evaluation of CD98 light chain-LAT1 as a potential marker of cancer stem-like cells in glioblastoma. Biochimica et Biophysica Acta (BBA). 2022;1869: 119303. https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119303.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"810_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115103","volume":"201","author":"N Cappoli","year":"2022","unstructured":"Cappoli N, Jenkinson MD, Dello Russo C, Dickens D. LAT1, a novel pharmacological target for the treatment of glioblastoma. Biochem Pharmacol. 2022;201: 115103. https:\/\/doi.org\/10.1016\/j.bcp.2022.115103.","journal-title":"Biochem Pharmacol"},{"key":"810_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41551-022-00956-5","volume":"7","author":"X Tian","year":"2023","unstructured":"Tian X, Liu X, Ding J, et al. An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice. Nat Biomed Eng. 2023;7:8\u201323. https:\/\/doi.org\/10.1038\/s41551-022-00956-5.","journal-title":"Nat Biomed Eng."},{"key":"810_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050678","author":"JA Combs","year":"2019","unstructured":"Combs JA, DeNicola GM. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11050678.","journal-title":"Cancers (Basel)"},{"key":"810_CR48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.mam.2012.07.002","volume":"34","author":"AB Pramod","year":"2013","unstructured":"Pramod AB, Foster J, Carvelli L, Henry LK. Slc6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med. 2013;34:197\u2013219. https:\/\/doi.org\/10.1016\/j.mam.2012.07.002.","journal-title":"Mol Aspects Med"},{"key":"810_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ajps.2014.04.004","volume":"9","author":"YD Bhutia","year":"2014","unstructured":"Bhutia YD, Babu E, Prasad PD, Ganapathy V. The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy. Asian J Pharm Sci. 2014;9:293\u2013303. https:\/\/doi.org\/10.1016\/j.ajps.2014.04.004.","journal-title":"Asian J Pharm Sci"},{"key":"810_CR50","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/s41422-020-0338-1","volume":"30","author":"M Tang","year":"2020","unstructured":"Tang M, Xie Q, Gimple RC, et al. Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Res. 2020;30:833\u201353. https:\/\/doi.org\/10.1038\/s41422-020-0338-1.","journal-title":"Cell Res"},{"key":"810_CR51","doi-asserted-by":"publisher","first-page":"22954","DOI":"10.18632\/oncotarget.14578","volume":"8","author":"C Xiang","year":"2017","unstructured":"Xiang C, Zhang ML, Zhao QZ, et al. LncRNA-SLC6A9-5:2: a potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction. Oncotarget. 2017;8:22954\u201367. https:\/\/doi.org\/10.18632\/oncotarget.14578.","journal-title":"Oncotarget"},{"key":"810_CR52","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3390\/biomedicines9121770","volume":"9","author":"CG Bierhals","year":"2021","unstructured":"Bierhals CG, Howard A, Hirst BH. Reduction of rapid proliferating tumour cell lines by inhibition of the specific glycine transporter GLYT1. Biomedicines. 2021;9:1770.","journal-title":"Biomedicines."},{"key":"810_CR53","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.mam.2012.05.004","volume":"34","author":"RJ Reimer","year":"2013","unstructured":"Reimer RJ. SLC17: a functionally diverse family of organic anion transporters. Mol Aspects Med. 2013;34:350\u20139. https:\/\/doi.org\/10.1016\/j.mam.2012.05.004.","journal-title":"Mol Aspects Med"},{"key":"810_CR54","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/neuonc\/noac108","volume":"24","author":"FL Ricklefs","year":"2022","unstructured":"Ricklefs FL, Drexler R, Wollmann K, et al. DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients. Neuro Oncol. 2022;24:1886\u201397. https:\/\/doi.org\/10.1093\/neuonc\/noac108.","journal-title":"Neuro Oncol"},{"key":"810_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071796","author":"L Corsi","year":"2019","unstructured":"Corsi L, Mescola A, Alessandrini A. Glutamate receptors and glioblastoma multiforme: an old \u201croute\u201d for new perspectives. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20071796.","journal-title":"Int J Mol Sci"},{"key":"810_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1515\/oncologie-2023-0280","volume":"26","author":"G Zhang","year":"2024","unstructured":"Zhang G, Wang N, Ma S, Wei Z, Tao P, Cai H. SLC25 family with energy metabolism and immunity in malignant tumors. Oncologie. 2024;26:65\u201377. https:\/\/doi.org\/10.1515\/oncologie-2023-0280.","journal-title":"Oncologie"},{"key":"810_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127511","volume":"253","author":"E Shin","year":"2023","unstructured":"Shin E, Kim B, Kang H, et al. Mitochondrial glutamate transporter SLC25A22 uni-directionally export glutamate for metabolic rewiring in radioresistant glioblastoma. Int J Biol Macromol. 2023;253: 127511. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.127511.","journal-title":"Int J Biol Macromol"},{"key":"810_CR58","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s00424-003-1091-2","volume":"447","author":"B Gasnier","year":"2004","unstructured":"Gasnier B. The SLC32 transporter, a key protein for the synaptic release of inhibitory amino acids. Pflugers Arch. 2004;447:756\u20139. https:\/\/doi.org\/10.1007\/s00424-003-1091-2.","journal-title":"Pflugers Arch"},{"key":"810_CR59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bbrc.2011.06.121","volume":"411","author":"H Shimizu","year":"2011","unstructured":"Shimizu H, Horii A, Sunamura M, et al. Identification of epigenetically silenced genes in human pancreatic cancer by a novel method \u201cmicroarray coupled with methyl-CpG targeted transcriptional activation\u201d (MeTA-array). Biochem Biophys Res Commun. 2011;411:162\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2011.06.121.","journal-title":"Biochem Biophys Res Commun"},{"key":"810_CR60","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1111\/j.1476-5381.2011.01438.x","volume":"164","author":"DT Thwaites","year":"2011","unstructured":"Thwaites DT, Anderson CM. The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport. Br J Pharmacol. 2011;164:1802\u201316. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01438.x.","journal-title":"Br J Pharmacol"},{"key":"810_CR61","doi-asserted-by":"publisher","first-page":"1260409","DOI":"10.3389\/fnins.2023.1260409","volume":"17","author":"Z Kaluzinska-Kolat","year":"2023","unstructured":"Kaluzinska-Kolat Z, Kolat D, Kosla K, Pluciennik E, Bednarek AK. Molecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit from WWOX tumor suppressor expression. Front Neurosci. 2023;17:1260409. https:\/\/doi.org\/10.3389\/fnins.2023.1260409.","journal-title":"Front Neurosci"},{"key":"810_CR62","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00424-013-1393-y","volume":"466","author":"S Broer","year":"2014","unstructured":"Broer S. The SLC38 family of sodium-amino acid co-transporters. Pflugers Arch. 2014;466:155\u201372. https:\/\/doi.org\/10.1007\/s00424-013-1393-y.","journal-title":"Pflugers Arch"},{"key":"810_CR63","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-230X-14-70","volume":"14","author":"J Xie","year":"2014","unstructured":"Xie J, Li P, Gao HF, Qian JX, Yuan LY, Wang JJ. Overexpression of SLC38A1 is associated with poorer prognosis in Chinese patients with gastric cancer. BMC Gastroenterol. 2014;14:70. https:\/\/doi.org\/10.1186\/1471-230X-14-70.","journal-title":"BMC Gastroenterol"},{"key":"810_CR64","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41416-021-01490-y","volume":"125","author":"J Li","year":"2021","unstructured":"Li J, Li MH, Wang TT, et al. Slc38a4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt\/beta-catenin\/MYC\/HMGCS2 axis. Br J Cancer. 2021;125:865\u201376. https:\/\/doi.org\/10.1038\/s41416-021-01490-y.","journal-title":"Br J Cancer"},{"key":"810_CR65","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat9528","author":"N Kory","year":"2018","unstructured":"Kory N, Wyant GA, Prakash G, et al. SFXN1 is a mitochondrial serine transporter required for one-carbon metabolism. Science. 2018. https:\/\/doi.org\/10.1126\/science.aat9528.","journal-title":"Science"},{"key":"810_CR66","doi-asserted-by":"publisher","DOI":"10.1515\/med-2023-0685","volume":"18","author":"D Yuan","year":"2023","unstructured":"Yuan D, Liu J, Sang W, Li Q. Comprehensive analysis of the role of SFXN family in breast cancer. Open Med. 2023;18: 20230685. https:\/\/doi.org\/10.1515\/med-2023-0685.","journal-title":"Open Med"},{"key":"810_CR67","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1111\/febs.16377","volume":"289","author":"LM Ledahawsky","year":"2022","unstructured":"Ledahawsky LM, Terzenidou ME, Edwards R, et al. The mitochondrial protein sideroflexin 3 (SFXN3) influences neurodegeneration pathways in vivo. FEBS J. 2022;289:3894\u2013914. https:\/\/doi.org\/10.1111\/febs.16377.","journal-title":"FEBS J"},{"key":"810_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.920136","volume":"13","author":"K Chen","year":"2022","unstructured":"Chen K, Gong S, Fang X, et al. Non-coding RNA-mediated high expression of SFXN3 as a prognostic biomarker associated with paclitaxel resistance and immunosuppressive microenvironment in head and neck cancer. Front Immunol. 2022;13: 920136. https:\/\/doi.org\/10.3389\/fimmu.2022.920136.","journal-title":"Front Immunol"},{"key":"810_CR69","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3171\/jns.1987.66.6.0865","volume":"66","author":"PJ Kelly","year":"1987","unstructured":"Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66:865\u201374. https:\/\/doi.org\/10.3171\/jns.1987.66.6.0865.","journal-title":"J Neurosurg"},{"key":"810_CR70","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/s0025-6196(12)65470-6","volume":"62","author":"PJ Kelly","year":"1987","unstructured":"Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc. 1987;62:450\u20139. https:\/\/doi.org\/10.1016\/s0025-6196(12)65470-6.","journal-title":"Mayo Clin Proc"},{"key":"810_CR71","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics. 2017;14:307\u201320. https:\/\/doi.org\/10.1007\/s13311-016-0507-6.","journal-title":"Neurotherapeutics"},{"key":"810_CR72","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963\u201372. https:\/\/doi.org\/10.1200\/JCO.2009.26.3541.","journal-title":"J Clin Oncol"},{"key":"810_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25030568","author":"LR Drake","year":"2020","unstructured":"Drake LR, Hillmer AT, Cai Z. Approaches to PET imaging of glioblastoma. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25030568.","journal-title":"Molecules"},{"key":"810_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf118","author":"MJ van den Bent","year":"2025","unstructured":"van den Bent MJ, Vogelbaum MA, Cloughesy T, et al. Response Assessment in Neuro-Oncology (RANO) 2009\u20132025: broad scope and implementation\u2014a progress report. Neuro Oncol. 2025. https:\/\/doi.org\/10.1093\/neuonc\/noaf118.","journal-title":"Neuro Oncol"},{"key":"810_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering5040104","author":"AM Najjar","year":"2018","unstructured":"Najjar AM, Johnson JM, Schellingerhout D. The emerging role of amino acid PET in neuro-oncology. Bioengineering. 2018. https:\/\/doi.org\/10.3390\/bioengineering5040104.","journal-title":"Bioengineering"},{"key":"810_CR76","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1038\/s41467-023-39731-8","volume":"14","author":"M Harat","year":"2023","unstructured":"Harat M, Rakowska J, Harat M, et al. Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma. Nat Commun. 2023;14:4572. https:\/\/doi.org\/10.1038\/s41467-023-39731-8.","journal-title":"Nat Commun"},{"key":"810_CR77","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3174\/ajnr.A7762","volume":"44","author":"N Soni","year":"2023","unstructured":"Soni N, Ora M, Jena A, et al. Amino acid tracer PET MRI in glioma management: what a neuroradiologist needs to know. AJNR Am J Neuroradiol. 2023;44:236\u201346. https:\/\/doi.org\/10.3174\/ajnr.A7762.","journal-title":"AJNR Am J Neuroradiol"},{"key":"810_CR78","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00726-014-1863-3","volume":"47","author":"A Habermeier","year":"2015","unstructured":"Habermeier A, Graf J, Sandhofer BF, Boissel JP, Roesch F, Closs EI. System l amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-l-tyrosine (FET). Amino Acids. 2015;47:335\u201344. https:\/\/doi.org\/10.1007\/s00726-014-1863-3.","journal-title":"Amino Acids"},{"key":"810_CR79","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13550-021-00865-9","volume":"11","author":"FJ Vettermann","year":"2021","unstructured":"Vettermann FJ, Diekmann C, Weidner L, et al. l-Type amino acid transporter (LAT) 1 expression in (18)F-FET-negative gliomas. EJNMMI Res. 2021;11:124. https:\/\/doi.org\/10.1186\/s13550-021-00865-9.","journal-title":"EJNMMI Res"},{"key":"810_CR80","doi-asserted-by":"publisher","unstructured":"Chehri S, Henriksen OM, Marner L, et al.: A prospective clinical study of the influence of oral protein intake on [(18)F]FET-PET uptake and test-retest repeatability in glioma. EJNMMI Res. 2024, 14:58. https:\/\/doi.org\/10.1186\/s13550-024-01119-0","DOI":"10.1186\/s13550-024-01119-0"},{"key":"810_CR81","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajps.2019.12.002","volume":"15","author":"L Zhang","year":"2020","unstructured":"Zhang L, Sui C, Yang W, Luo Q. Amino acid transporters: emerging roles in drug delivery for tumor-targeting therapy. Asian J Pharm Sci. 2020;15:192\u2013206. https:\/\/doi.org\/10.1016\/j.ajps.2019.12.002.","journal-title":"Asian J Pharm Sci"},{"key":"810_CR82","doi-asserted-by":"publisher","first-page":"12860","DOI":"10.1038\/s41598-019-49009-z","volume":"9","author":"J Huttunen","year":"2019","unstructured":"Huttunen J, Peltokangas S, Gynther M, et al. L-type amino acid transporter 1 (LAT1\/Lat1)-utilizing prodrugs can improve the delivery of drugs into neurons, astrocytes and microglia. Sci Rep. 2019;9:12860. https:\/\/doi.org\/10.1038\/s41598-019-49009-z.","journal-title":"Sci Rep"},{"key":"810_CR83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11095-020-02826-8","volume":"37","author":"E Puris","year":"2020","unstructured":"Puris E, Gynther M, Auriola S, Huttunen KM. L-type amino acid transporter 1 as a target for drug delivery. Pharm Res. 2020;37:88. https:\/\/doi.org\/10.1007\/s11095-020-02826-8.","journal-title":"Pharm Res"},{"key":"810_CR84","doi-asserted-by":"publisher","first-page":"107327482412515","DOI":"10.1177\/10732748241251583","volume":"31","author":"R Norrsell","year":"2024","unstructured":"Norrsell R, Bauden M, Andersson R, Ansari D. L-type amino acid transporter 1 as a therapeutic target in pancreatic cancer. Cancer Control. 2024;31:10732748241251584. https:\/\/doi.org\/10.1177\/10732748241251583.","journal-title":"Cancer Control"},{"key":"810_CR85","unstructured":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT). Edited by Eli L, Company, Celgene, Puma Biotechnology I, Accelerate Brain Cancer C, Quadriga Biosciences I. 2016."},{"key":"810_CR86","unstructured":"Phase IIa study assessing QBS72S for treating brain metastases. Edited by Quadriga Biosciences I. 2022."},{"key":"810_CR87","doi-asserted-by":"publisher","first-page":"8276139","DOI":"10.1155\/2018\/8276139","volume":"2018","author":"X Li","year":"2018","unstructured":"Li X, Liu Y, Tian H. Current developments in Pt(IV) prodrugs conjugated with bioactive ligands. Bioinorg Chem Appl. 2018;2018:8276139. https:\/\/doi.org\/10.1155\/2018\/8276139.","journal-title":"Bioinorg Chem Appl"},{"key":"810_CR88","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1959\u201372. https:\/\/doi.org\/10.1038\/jcbfm.2012.126.","journal-title":"J Cereb Blood Flow Metab"},{"key":"810_CR89","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2016.1153568","volume":"4","author":"AM Grabrucker","year":"2016","unstructured":"Grabrucker AM, Ruozi B, Belletti D, et al. Nanoparticle transport across the blood brain barrier. Tissue Barriers. 2016;4: e1153568. https:\/\/doi.org\/10.1080\/21688370.2016.1153568.","journal-title":"Tissue Barriers"},{"key":"810_CR90","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8:217. https:\/\/doi.org\/10.1038\/s41392-023-01481-w.","journal-title":"Signal Transduct Target Ther"},{"key":"810_CR91","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1007\/s12274-023-5568-3","volume":"16","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Cheng Q, Xue Y, et al. LAT1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy. Nano Res. 2023;16:9743\u201351.","journal-title":"Nano Res"},{"key":"810_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2023.101056","volume":"6","author":"JL Bullock","year":"2023","unstructured":"Bullock JL, Gillette DD, Smith JA. Small molecule, nanoparticle and liposomal strategies for LAT1-mediated chemotherapy delivery. Results Chem. 2023;6: 101056. https:\/\/doi.org\/10.1016\/j.rechem.2023.101056.","journal-title":"Results Chem"},{"key":"810_CR93","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1080\/10717544.2017.1377316","volume":"24","author":"L Kou","year":"2017","unstructured":"Kou L, Yao Q, Sivaprakasam S, et al. Dual targeting of L-carnitine-conjugated nanoparticles to OCTN2 and ATB(0,+) to deliver chemotherapeutic agents for colon cancer therapy. Drug Deliv. 2017;24:1338\u201349. https:\/\/doi.org\/10.1080\/10717544.2017.1377316.","journal-title":"Drug Deliv"},{"key":"810_CR94","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.bbcan.2019.04.006","volume":"1871","author":"PY Liyanage","year":"2019","unstructured":"Liyanage PY, Hettiarachchi SD, Zhou Y, et al. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta (BBA). 2019;1871:419\u201333. https:\/\/doi.org\/10.1016\/j.bbcan.2019.04.006.","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"810_CR95","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-319-41129-3_2","volume-title":"Natural polymer drug delivery systems: nanoparticles, plants, and algae","author":"S Bhatia","year":"2016","unstructured":"Bhatia S. Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications. In: Bhatia S, editor. Natural polymer drug delivery systems: nanoparticles, plants, and algae. Cham: Springer International Publishing; 2016. p. 33\u201393. https:\/\/doi.org\/10.1007\/978-3-319-41129-3_2."},{"key":"810_CR96","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1039\/c8nr08970a","volume":"11","author":"SD Hettiarachchi","year":"2019","unstructured":"Hettiarachchi SD, Graham RM, Mintz KJ, et al. Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors. Nanoscale. 2019;11:6192\u2013205. https:\/\/doi.org\/10.1039\/c8nr08970a.","journal-title":"Nanoscale"},{"key":"810_CR97","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505\u201322. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.043.","journal-title":"J Control Release"},{"key":"810_CR98","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1080\/21691401.2016.1276924","volume":"45","author":"A Sahin","year":"2017","unstructured":"Sahin A, Esendagli G, Yerlikaya F, et al. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles\u2019 characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol. 2017;45:1657\u201364. https:\/\/doi.org\/10.1080\/21691401.2016.1276924.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"810_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054333","author":"X Guo","year":"2023","unstructured":"Guo X, Zuo X, Zhou Z, et al. PLGA-based micro\/nanoparticles: an overview of their applications in respiratory diseases. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24054333.","journal-title":"Int J Mol Sci"},{"key":"810_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411722","author":"M AbdEl-Haq","year":"2023","unstructured":"AbdEl-Haq M, Kumar A, Ait Mohand FE, Kravchenko-Balasha N, Rottenberg Y, Domb AJ. Paclitaxel delivery to the brain for glioblastoma treatment. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241411722.","journal-title":"Int J Mol Sci"},{"key":"810_CR101","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijpharm.2018.04.062","volume":"545","author":"MJ Ramalho","year":"2018","unstructured":"Ramalho MJ, Sevin E, Gosselet F, et al. Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm. 2018;545:84\u201392. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.04.062.","journal-title":"Int J Pharm"},{"key":"810_CR102","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.colsurfb.2016.01.041","volume":"141","author":"L Li","year":"2016","unstructured":"Li L, Di X, Zhang S, et al. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Colloids Surf B Biointerfaces. 2016;141:260\u20137. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.01.041.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"810_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2022.100478","volume":"4","author":"MAR Khan","year":"2022","unstructured":"Khan MAR, Al Mamun MS, Habib MA, et al. A review on gold nanoparticles: biological synthesis, characterizations, and analytical applications. Results Chem. 2022;4: 100478. https:\/\/doi.org\/10.1016\/j.rechem.2022.100478.","journal-title":"Results Chem"},{"key":"810_CR104","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccr.2017.08.020","volume":"352","author":"J Zhou","year":"2017","unstructured":"Zhou J, Cao Z, Panwar N, et al. Functionalized gold nanorods for nanomedicine: past, present and future. Coord Chem Rev. 2017;352:15\u201366. https:\/\/doi.org\/10.1016\/j.ccr.2017.08.020.","journal-title":"Coord Chem Rev"},{"key":"810_CR105","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12943-023-01798-8","volume":"22","author":"P Kesharwani","year":"2023","unstructured":"Kesharwani P, Ma R, Sang L, et al. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol Cancer. 2023;22:98. https:\/\/doi.org\/10.1186\/s12943-023-01798-8.","journal-title":"Mol Cancer"},{"key":"810_CR106","doi-asserted-by":"publisher","first-page":"39259","DOI":"10.1021\/acsami.7b14851","volume":"9","author":"ZY Ong","year":"2017","unstructured":"Ong ZY, Chen S, Nabavi E, et al. Multibranched gold nanoparticles with intrinsic LAT-1 targeting capabilities for selective photothermal therapy of breast cancer. ACS Appl Mater Interfaces. 2017;9:39259\u201370. https:\/\/doi.org\/10.1021\/acsami.7b14851.","journal-title":"ACS Appl Mater Interfaces"},{"key":"810_CR107","doi-asserted-by":"publisher","first-page":"8774","DOI":"10.1039\/D0CS01121E","volume":"49","author":"ZR Goddard","year":"2020","unstructured":"Goddard ZR, Mar\u00edn MJ, Russell DA, Searcey M. Active targeting of gold nanoparticles as cancer therapeutics. Chem Soc Rev. 2020;49:8774\u201389. https:\/\/doi.org\/10.1039\/D0CS01121E.","journal-title":"Chem Soc Rev"},{"key":"810_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124301","volume":"660","author":"S Qureshi","year":"2024","unstructured":"Qureshi S, Anjum S, Hussain M, et al. A recent insight of applications of gold nanoparticles in glioblastoma multiforme therapy. Int J Pharm. 2024;660: 124301. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124301.","journal-title":"Int J Pharm"},{"key":"810_CR109","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9\u201322. https:\/\/doi.org\/10.1038\/nrc2748.","journal-title":"Nat Rev Cancer"},{"key":"810_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09394","volume":"8","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8: e09394. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09394.","journal-title":"Heliyon"},{"key":"810_CR111","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1872211310666161004155757","volume":"10","author":"S Jha","year":"2016","unstructured":"Jha S, Sharma PK, Malviya R. Liposomal drug delivery system for cancer therapy: advancement and patents. Recent Pat Drug Deliv Formul. 2016;10:177\u201383. https:\/\/doi.org\/10.2174\/1872211310666161004155757.","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"810_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics8030025","author":"SG Ong","year":"2016","unstructured":"Ong SG, Ming LC, Lee KS, Yuen KH. Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics. 2016. https:\/\/doi.org\/10.3390\/pharmaceutics8030025.","journal-title":"Pharmaceutics"},{"key":"810_CR113","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.2147\/IJN.S470478","volume":"19","author":"Y Gan","year":"2024","unstructured":"Gan Y, Yu Y, Xu H, Piao H. Liposomal nanomaterials: a rising star in glioma treatment. Int J Nanomed. 2024;19:6757\u201376. https:\/\/doi.org\/10.2147\/IJN.S470478.","journal-title":"Int J Nanomed"},{"key":"810_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105060","volume":"89","author":"S Nangare","year":"2023","unstructured":"Nangare S, Chandankar S, Patil P. Design of carbon and graphene quantum dots based nanotheranostics applications for glioblastoma management: recent advanced and future prospects. J Drug Deliv Sci Technol. 2023;89: 105060. https:\/\/doi.org\/10.1016\/j.jddst.2023.105060.","journal-title":"J Drug Deliv Sci Technol"},{"key":"810_CR115","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41551-020-0540-y","volume":"4","author":"S Li","year":"2020","unstructured":"Li S, Su W, Wu H, et al. Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids. Nat Biomed Eng. 2020;4:704\u201316. https:\/\/doi.org\/10.1038\/s41551-020-0540-y.","journal-title":"Nat Biomed Eng"},{"key":"810_CR116","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2019.10.037","volume":"316","author":"Z Wang","year":"2019","unstructured":"Wang Z, Chi D, Wu X, et al. Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB(0,+) for efficient tumor therapy. J Control Release. 2019;316:22\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2019.10.037.","journal-title":"J Control Release"},{"key":"810_CR117","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.addr.2012.09.041","volume":"65","author":"S Xu","year":"2013","unstructured":"Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev. 2013;65:121\u201338. https:\/\/doi.org\/10.1016\/j.addr.2012.09.041.","journal-title":"Adv Drug Deliv Rev"},{"key":"810_CR118","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.nano.2016.11.012","volume":"13","author":"L Li","year":"2017","unstructured":"Li L, Di X, Wu M, et al. Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: toward a novel active targeting strategy in breast cancer therapy. Nanomedicine. 2017;13:987\u201398. https:\/\/doi.org\/10.1016\/j.nano.2016.11.012.","journal-title":"Nanomedicine"},{"key":"810_CR119","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.1039\/d2nr02063g","volume":"14","author":"E Kirbas Cilingir","year":"2022","unstructured":"Kirbas Cilingir E, Sankaran M, Garber JM, et al. Surface modification of carbon nitride dots by nanoarchitectonics for better drug loading and higher cancer selectivity. Nanoscale. 2022;14:9686\u2013701. https:\/\/doi.org\/10.1039\/d2nr02063g.","journal-title":"Nanoscale"},{"key":"810_CR120","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41419-022-05526-w","volume":"13","author":"L Han","year":"2022","unstructured":"Han L, Zhou J, Li L, et al. SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma. Cell Death Dis. 2022;13:1071. https:\/\/doi.org\/10.1038\/s41419-022-05526-w.","journal-title":"Cell Death Dis"},{"key":"810_CR121","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","volume":"38","author":"N Okano","year":"2020","unstructured":"Okano N, Naruge D, Kawai K, et al. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Investig New Drugs. 2020;38:1495\u2013506. https:\/\/doi.org\/10.1007\/s10637-020-00924-3.","journal-title":"Investig New Drugs"},{"key":"810_CR122","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10014-005-0188-z","volume":"22","author":"H Nawashiro","year":"2005","unstructured":"Nawashiro H, Otani N, Uozumi Y, et al. High expression of l-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathol. 2005;22:89\u201391. https:\/\/doi.org\/10.1007\/s10014-005-0188-z.","journal-title":"Brain Tumor Pathol"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00810-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:53:04Z","timestamp":1761947584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":122,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00810-9","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the conduct of this study or the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emanuella M. Brito, Emma M. Baker, Nicholas Ahye, MD, Bryan Lieber, MD, Sajini Hettiarachchi, Maria J. Moreno Hollweg, Sabrin Safar, Steven Vanni, DO, and Regina M. Graham, PhD declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}},{"value":"Emanuella M. Brito made substantial contributions to the conception and design of the work, drafted the manuscript, and approved the final version. Emma M. Baker and Sajini Hettiarachchi contributed to the drafting and critical revision of the manuscript and to figure development. Maria J. Moreno Hollweg and Sabrin Safar contributed to the acquisition and interpretation of relevant literature and figure preparation. Nicholas Ahye, MD, Bryan Lieber, MD, and Steven Vanni, DO, contributed to the interpretation of clinical content and critically revised the manuscript for important intellectual content. Regina M. Graham, PhD, provided supervision, critical revision of the manuscript, and final approval of the version to be published. All authors meet the ICMJE criteria for authorship, have approved the submitted version, and agree to be accountable for all aspects of the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}